Literature DB >> 24575881

Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.

Alessandra Drummond1, Janine Pichler1, Giuseppe Argenziano2, Iris Zalaudek2,3, Caterina Longo2, Aimilios Lallas2, Simonetta Piana2, Elvira Moscarella2.   

Abstract

Basal cell naevus syndrome is an inherited autosomal dominant genetic disorder characterised by multiple basal cell carcinomas (BCC), skeletal, neurological and opthalmological abnormalities. The treatment of choice of the often multiple and large BCC consists of a combined approach including surgery, liquid nitrogen and other topical treatment modalities. Imiquimod 5% cream is an immune-response-modifying drug with antiviral and anti-tumour activity. Recent reports have associated the immune-stimulant properties of imiquimod with the exacerbation of several autoimmune skin diseases, such as eczema, psoriasis, vitiligo and lichenoid dermatitis. Here we report a patient with basal cell naevus syndrome who developed a lichen planopilaris on the same site of the scalp, which had been previously treated with two cycles of imiquimod for multiple BCC.
© 2014 The Australasian College of Dermatologists.

Entities:  

Keywords:  Gorlin-Goltz; imiquimod 5%; lichen planopilaris

Mesh:

Substances:

Year:  2014        PMID: 24575881     DOI: 10.1111/ajd.12151

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  2 in total

1.  [Eruptive epidermoid cysts after imiquimod treatment of recurrent basal cell carcinoma : A case report].

Authors:  Nora Woltsche; Laila El-Shabrawi-Caelen; Teresa Deinlein; Romana Kupsa; Martha Gschwandtner; Rainer Hofmann-Wellenhof; Iris Zalaudek
Journal:  Hautarzt       Date:  2019-05       Impact factor: 0.751

2.  Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients.

Authors:  N Brankov; R Z Conic; N Atanaskova-Mesinkovska; M Piliang; W F Bergfeld
Journal:  Int J Womens Dermatol       Date:  2018-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.